Additionally, Brouwer-Visser et.al indicated that suppressing the expression level of IGF2 in ovarian cancer cells via employing RNA interference technology could elevate paclitaxel sensitivity and could restore sensitivity to both microtubule-stabilizing and destabilizing agents (Brouwer-Visser et al., 2014). The gene discussed is IGF2; the disease is ovarian carcinoma.